FMP

FMP

Enter

HBP.TO - Helix BioPharma Corp.

Profile of Helix BioPharma Corp.(HBP.TO), Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for

About

ceo

Mr. Jacek Antas

sector

Healthcare

industry

Biotechnology

website

https://www.helixbiopharma.com

exchange

TSX

Description

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.

CIK

N/A

ISIN

CA4229101098

CUSIP

422910109

Address

9120 Leslie Street

Phone

905 841 2300

Country

CA

Employee

9

IPO Date

Aug 13, 1996

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep